AtriCure Q2 revenue beats estimates
Overview
AtriCure Q2 revenue rises 17.1% yr/yr, beating analyst expectations, per LSEG data
Adjusted EPS for Q2 beats estimates, improving to a loss of $0.02
Adjusted EBITDA increases significantly, surpassing analyst forecasts, per LSEG data
Outlook
AtriCure projects full-year 2025 revenue between $527 mln and $533 mln
Company expects full-year 2025 adjusted EBITDA of $49 mln to $52 mln
AtriCure anticipates full-year 2025 adjusted loss per share of $0.34 to $0.39
Company expects modest cash flow generation for full-year 2025
Result Drivers
PRODUCT ADOPTION - Revenue growth driven by increased adoption of AtriCure's Afib, LAA management, and post-operative pain management products
KEY PRODUCT LINES - U.S. revenue boosted by sales of AtriClip FLEX·Mini, EnCompass clamp, and cryoSPHERE MAX probe
INTERNATIONAL GROWTH - Significant international revenue increase across all franchises and geographic regions
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $136.10 mln | $130.20 mln (9 Analysts) |
Q2 Adjusted EPS | Beat | -$0.02 | -$0.17 (9 Analysts) |
Q2 Adjusted EBITDA | Beat | $15.40 mln | $10.10 mln (7 Analysts) |
Q2 Gross Margin | 74.5% | ||
Q2 Gross Profit | $101.50 mln | ||
Q2 Operating Income | -$6.20 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AtriCure Inc is $50.50, about 34.2% above its July 28 closing price of $33.22
Press Release:
